Lisheng Wang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4388534/publications.pdf

Version: 2024-02-01

39 papers	2,184 citations	361413 20 h-index	302126 39 g-index
39 all docs	39 docs citations	39 times ranked	3757 citing authors

#	Article	IF	Citations
1	Applications of Extracellular Vesicles in Triple-Negative Breast Cancer. Cancers, 2022, 14, 451.	3.7	14
2	The Potential of Natural Products in the Treatment of Triple-negative Breast Cancer. Current Cancer Drug Targets, 2022, 22, 388-403.	1.6	16
3	Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	1
4	Molecularly Imprinted Polymer Nanoparticles: An Emerging Versatile Platform for Cancer Therapy. Angewandte Chemie - International Edition, 2021, 60, 3858-3869.	13.8	113
5	Molecularly Imprinted Polymerâ€Based Smart Prodrug Delivery System for Specific Targeting, Prolonged Retention, and Tumor Microenvironmentâ€Triggered Release. Angewandte Chemie - International Edition, 2021, 60, 2663-2667.	13.8	90
6	Hollow-fiber bioreactor production of extracellular vesicles from human bone marrow mesenchymal stromal cells yields nanovesicles that mirrors the immuno-modulatory antigenic signature of the producer cell. Stem Cell Research and Therapy, 2021, 12, 127.	5.5	55
7	Polysaccharide-rich extract from Polygonatum sibiricum protects hematopoiesis in bone marrow suppressed by triple negative breast cancer. Biomedicine and Pharmacotherapy, 2021, 137, 111338.	5.6	21
8	Expression of Nutrient Transporters on NK Cells During Murine Cytomegalovirus Infection Is MyD88-Dependent. Frontiers in Immunology, 2021, 12, 654225.	4.8	5
9	Single Immunization of a Vaccine Vectored by a Novel Recombinant Vaccinia Virus Affords Effective Protection Against Respiratory Syncytial Virus Infection in Cotton Rats. Frontiers in Immunology, 2021, 12, 747866.	4.8	7
10	A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature. Cell Death and Disease, 2021, 12, 8.	6.3	25
11	Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages. IScience, 2021, 24, 103328.	4.1	4
12	DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model. Frontiers in Immunology, 2021, 12, 785349.	4.8	7
13	Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. Cancers, 2020, 12, 3529.	3.7	60
14	Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 9125.	4.1	26
15	Dysregulation of Ephrin receptor and PPAR signaling pathways in neural progenitor cells infected by Zika virus. Emerging Microbes and Infections, 2020, 9, 2046-2060.	6.5	16
16	Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells. International Journal of Molecular Sciences, 2020, 21, 5788.	4.1	11
17	Nanoparticles Loaded with Wnt and YAP/Mevalonate Inhibitors in Combination with Paclitaxel Stop the Growth of TNBC Patientâ€Derived Xenografts and Diminish Tumorigenesis. Advanced Therapeutics, 2020, 3, 2000123.	3.2	1
18	The entry of nanoparticles into solid tumours. Nature Materials, 2020, 19, 566-575.	27.5	1,036

#	Article	IF	Citations
19	CSCs in Breast Cancerâ€"One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs. Cancers, 2019, 11, 1128.	3.7	29
20	PD-1 of Sigmodon hispidus: Gene identification, characterization and preliminary evaluation of expression in inactivated RSV vaccine-induced enhanced respiratory disease. Scientific Reports, 2019, 9, 11638.	3.3	1
21	Wnt Signaling in Cancer Metabolism and Immunity. Cancers, 2019, 11, 904.	3.7	77
22	Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy. Molecular Cancer Therapeutics, 2019, 18, 1755-1764.	4.1	17
23	Interleukin-18 up-regulates amino acid transporters and facilitates amino acidâ€"induced mTORC1 activation in natural killer cells. Journal of Biological Chemistry, 2019, 294, 4644-4655.	3.4	53
24	Chitosan alters inactivated respiratory syncytial virus vaccine elicited immune responses without affecting lung histopathology in mice. Vaccine, 2019, 37, 4031-4039.	3.8	25
25	Dual inhibition of Wnt and Yesâ€associated protein signaling retards the growth of tripleâ€negative breast cancer in both mesenchymal and epithelial states. Molecular Oncology, 2018, 12, 423-440.	4.6	54
26	Targeting CD40 enhances antibody- and CD8-mediated protection against respiratory syncytial virus infection. Scientific Reports, 2018, 8, 16648.	3.3	8
27	Identification of immunodominant CD8 epitope in the stalk domain of influenza B viral hemagglutinin. Biochemical and Biophysical Research Communications, 2018, 502, 226-231.	2.1	6
28	Co-inhibition of mTORC1, HDAC and ESR1Î± retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death and Disease, 2018, 9, 815.	6.3	34
29	An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death and Disease, 2017, 8, e2932-e2932.	6.3	76
30	Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies. Expert Review of Vaccines, 2017, 16, 351-360.	4.4	27
31	Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors. Oncotarget, 2017, 8, 113269-113281.	1.8	44
32	E-cadherin adhesion-mediated Wnt activation for mesoderm specification in human embryonic stem cells needs a soft mattress. Stem Cell Investigation, 2016, 3, 77-77.	3.0	2
33	Cardamonin reduces chemotherapy-enriched breast cancer stem-like cellsin vitroandin vivo. Oncotarget, 2016, 7, 771-785.	1.8	66
34	Both bulk and cancer stem cell subpopulations in tripleâ€negative breast cancer are susceptible to Wnt, <scp>HDAC</scp>, and <scp>ER</scp>Î± coinhibition. FEBS Letters, 2016, 590, 4606-4616.	2.8	28
35	The other face of TLR3: A driving force of breast cancer stem cells. Molecular and Cellular Oncology, 2015, 2, e981443.	0.7	10
36	Differential expression, distinct localization and opposite effect on Golgi structure and cell differentiation by a novel splice variant of human PRMT5. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 2444-2452.	4.1	31

#	Article	IF	Citations
37	MFG-E8 Is Critical for Embryonic Stem Cell-Mediated T Cell Immunomodulation. Stem Cell Reports, 2015, 5, 741-752.	4.8	17
38	Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives. Current Stem Cell Research and Therapy, 2013, 9, 63-72.	1.3	53
39	Endothelial and Hematopoietic Cell Fate of Human Embryonic Stem Cells. Trends in Cardiovascular Medicine, 2006, 16, 89-94.	4.9	18